BROSSARD, Quebec, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical eye-related health issues using advanced technology based on Artificial Intelligence (AI), is pleased to announce that it will be presenting at the Centurion One Capital 9th Annual Conference in Toronto, Canada March 5th 2026. This exclusive gathering unites the most significant group of Canadian investors in sea ...

Core Insights - Diagnos Inc. has received a federal investment exceeding 1 million CAD to enhance the development of AI for retinal image analysis [1][2] - The initiative highlights Canada's strong research ecosystem and DIAGNOS' commitment to advancing AI solutions for eye health [2][5] Company Contributions - DIAGNOS is contributing 500,000 CAD over five years, matching the NSERC-Mitacs Alliance grant, to support the research program [2] - The financial contribution is aimed at establishing an industrial research Chair at ÉTS, reinforcing DIAGNOS' long-term commitment to retinal AI innovation [2] Research Program Details - The research program titled "Towards the Next Generation of Deep Learning Algorithms for Retinal Image Analysis" aims to improve accuracy and clinical relevance in retinal disease detection [3] - The project is in an advanced recruitment stage, with researcher onboarding nearing completion, and focuses on translating academic advances into practical AI algorithms [4] Collaboration and Talent Development - The collaboration with ÉTS is part of DIAGNOS' strategy to leverage academic research for innovation in AI-driven retinal health solutions [5] - The funding supports eight Highly Qualified Personnel, including five graduate students and three postdoctoral researchers, to develop expertise at the intersection of AI and healthcare [7]

BROSSARD, Quebec, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces the engagement of Investor Brand Network (“IBN”) to provide corporate communication and awareness solutions to the Corporation. As per the agreement signed between IBN and DIAGNOS, IBN is entitled to a monthly compensation of US$6,400, pay ...

BROSSARD, Quebec, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in applying techniques in Artificial Intelligence (AI) for the early detection of eye-related health issues, is pleased to announce the appointment of Dr. Ismail Ben Ayed, as Chief Artificial Intelligence (AI) Scientist. Mr. Ben Ayed is an expert in medical image analysis algorithms, machine learning and computer vision. Mr. Ben Ayed will guide the Company’ ...

Not for distribution to United States newswire services or for dissemination in the United States. BROSSARD, Quebec, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Company”) (TSXV: ADK and OTCQB: DGNOF) is pleased to announce the successful closing of its previously announced upsized private placement (the “Offering”) of units of the Company (the “Units”). A total of 13,337,262 Units, including pursuant to an exercise of the over-allotment option, were sold under the Offering at a price o ...

Core Viewpoint - Diagnos Inc. has announced an upsized brokered private placement due to strong investor demand, aiming to raise approximately $3,650,000 by issuing up to 12,166,667 units at $0.30 per unit [1][2]. Group 1: Offering Details - Each unit consists of one common share and one common share purchase warrant, with the warrant allowing the purchase of one share at $0.40 for 18 months post-closing [2]. - The offering is led by Centurion One Capital Corp. as the lead agent and sole bookrunner, with proceeds allocated for regulatory affairs, product development, business development, and general corporate purposes [3]. - The offering is expected to close around December 3, 2025, subject to necessary approvals, including from the TSX Venture Exchange [5]. Group 2: Participation and Compliance - Certain insiders of the company and lead agent may acquire up to approximately 50% of the offering, which will be considered a related party transaction but is expected to be exempt from formal valuation and minority shareholder approval requirements [6]. - The units will be offered via private placement in specific Canadian provinces and the U.S. under an exemption from registration requirements [4]. Group 3: Company Overview - Diagnos Inc. is a publicly traded Canadian corporation focused on early detection of critical eye-related health issues, utilizing artificial intelligence to enhance diagnostic accuracy and improve patient outcomes globally [8].

Core Points - Diagnos Inc. intends to extend the exercise period of 3,502,931 stock warrants to August 5, 2026, subject to TSX Venture Exchange consent [1][2] - The exercise price of the warrants remains unchanged at $0.40 per common share during the extended period [2] Company Overview - Diagnos Inc. is a Canadian corporation focused on the early detection of critical eye-related health issues using Artificial Intelligence [4] - The company aims to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes globally [4]

Core Points - Diagnos Inc. has engaged Centurion One Capital Corp. as the lead agent for a brokered private placement to raise up to approximately $2,000,000 through the sale of up to 6,666,667 units at an issue price of $0.30 per unit [1] - Each unit consists of one common share and one common share purchase warrant, with the warrant exercisable at $0.40 per share for 18 months [1] - The offering is expected to close around December 3, 2025, subject to necessary approvals [4] Use of Proceeds - The gross proceeds from the offering will be allocated for regulatory affairs, product development, business development, and general corporate purposes [2] Offering Details - The units will be offered via private placement in British Columbia, Alberta, Ontario, Quebec, and the United States under an exemption from registration requirements [3] - Related parties of the company may acquire up to approximately 50% of the offering, which will be considered a related party transaction [5] Company Overview - Diagnos Inc. is a publicly traded Canadian corporation focused on early detection of critical eye-related health issues using Artificial Intelligence to enhance diagnostic accuracy and improve patient outcomes [7]

BROSSARD, Quebec, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces that Dr. Pierre-Luc Charlebois has joined the Corporation’s Advisory Board. Along with fellow members, Dr. Tomas J. Philipson, former vice chairman of the White House Council of Economic Advisers, Mr. Ed Weiner, a seasoned entrepreneur, an ...

Core Points - Diagnos Inc. intends to extend the exercise period of 1,125,000 stock warrants from November 9, 2025, to August 5, 2026, subject to TSX Venture Exchange consent [1][2] - The exercise price of the warrants will remain unchanged at $0.40 per common share during the extended period [2] Company Overview - Diagnos Inc. is a publicly traded Canadian corporation focused on the early detection of critical eye-related health issues using advanced Artificial Intelligence technology [4] - The company's goal is to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes globally [4]